Search Results - "FELTEN, Sara"

Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51 by Daniels, Thomas B., M.D, Brown, Paul D., M.D, Felten, Sara J., B.S, Wu, Wenting, Ph.D, Buckner, Jan C., M.D, Arusell, Robert M., M.D, Curran, Walter J., M.D, Abrams, Ross A., M.D, Schiff, David, M.D, Shaw, Edward G., M.D

“…Purpose A prognostic index for survival was constructed and validated from patient data from two European Organisation for Research and Treatment of Cancer…”
Get full text

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab by Huang, Raymond Y, Rahman, Rifaquat, Ballman, Karla V, Felten, Sara J, Anderson, S Keith, Ellingson, Benjamin M, Nayak, Lakshmi, Lee, Eudocia Q, Abrey, Lauren E, Galanis, Evanthia, Reardon, David A, Pope, Whitney B, Cloughesy, Timothy F, Wen, Patrick Y

“…The RANO criteria have not been assessed using outcome data from prospective trials. We examined the radiologic data of patients with recurrent glioblastoma…”
Get full text

Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma by BROWN, Paul D, JENSEN, Ashley W, FELTEN, Sara J, BALLMAN, Karla V, SCHAEFER, Paul L, JAECKLE, Kurt A, CERHAN, Jane H, BUCKNER, Jan C

“…There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more…”
Get full text

Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy by Ellingson, Marissa S., Hart, Steven N., Kalari, Krishna R., Suman, Vera, Schahl, Kimberly A., Dockter, Travis J., Felten, Sara J., Sinnwell, Jason P., Thompson, Kevin J., Tang, Xiaojia, Vedell, Peter T., Barman, Poulami, Sicotte, Hugues, Eckel-Passow, Jeanette E., Northfelt, Donald W., Gray, Richard J., McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Ingle, James N., Moyer, Ann M., Visscher, Daniel W., Jones, Katie, Conners, Amy, McDonough, Michelle, Wieben, Eric D., Wang, Liewei, Weinshilboum, Richard, Boughey, Judy C., Goetz, Matthew P.

“…When sequencing blood and tumor samples to identify targetable somatic variants for cancer therapy, clinically relevant germline variants may be uncovered. We…”
Get full text

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data by MOLINA, Julian R, KAUFMANN, Scott H, JEWELL, Roxanne C, FELTEN, Sara J, MANDREKAR, Sumithra, ADJEI, Alex A, ERLICHMAN, Charles, REID, Joel M, RUBIN, Stephen D, GALVEZ-PERALTA, Marina, FRIEDMAN, Robert, FLATTEN, Karen S, KOCH, Kevin M, GILMER, Tona M, MULLIN, Robert J

“…Purpose: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals…”
Get full text

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results by Santisteban, Marta, Buckner, Jan C., Reid, Joel M., Wu, Wenting, Scheithauer, Bernd W., Ames, Matthew M., Felten, Sara J., Nikcevich, Daniel A., Wiesenfeld, Martin, Jaeckle, Kurt A., Galanis, Evanthia

“…Purpose The aims of this trial were to assess the safety and efficacy of two different dosing schedules of irinotecan (CPT-11) in recurrent glioma patients, to…”
Get full text

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin by Furth, Alfred F., Mandrekar, Sumithra J., Tan, Angelina D., Rau, Andrea, Felten, Sara J., Ames, Matthew M., Adjei, Alex A., Erlichman, Charles, Reid, Joel M.

“…Purpose The Hsp90-directed anticancer agent 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) is currently undergoing phase I and phase II clinical…”
Get full text

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma by JENKINS, Robert B, BLAIR, Hilary, SHAW, Edward G, BUCKNER, Jan C, BALLMAN, Karla V, GIANNINI, Caterina, ARUSELL, Robert M, LAW, Mark, FLYNN, Heather, PASSE, Sandra, FELTEN, Sara, BROWN, Paul D

“…Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with anaplastic oligodendroglioma…”
Get full text

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer by Goetz, Matthew P, Kalari, Krishna R, Suman, Vera J, Moyer, Ann M, Yu, Jia, Visscher, Daniel W, Dockter, Travis J, Vedell, Peter T, Sinnwell, Jason P, Tang, Xiaojia, Thompson, Kevin J, McLaughlin, Sarah A, Moreno-Aspitia, Alvaro, Copland, John A, Northfelt, Donald W, Gray, Richard J, Hunt, Katie, Conners, Amy, Sicotte, Hugues, Eckel-Passow, Jeanette E, Kocher, Jean-Pierre, Ingle, James N, Ellingson, Marissa S, McDonough, Michelle, Wieben, Eric D, Weinshilboum, Richard, Wang, Liewei, Boughey, Judy C

“…Breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC) have increased recurrence risk. Molecular characterization, knowledge of NAC…”
Get full text

Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors by Rausch, Sarah M., Clark, Matthew M., Patten, Christi, Liu, Heshan, Felten, Sara, Li, Yafei, Sloan, Jeff, Yang, Ping

“…BACKGROUND: Previous research has demonstrated that many lung cancer survivors report difficulties with symptom control and experience a poor quality of life…”
Get full text

SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors by Rausch, Sarah M, Gonzalez, Brian D, Clark, Matthew M, Patten, Christi, Felten, Sara, Liu, Heshan, Li, Yafei, Sloan, Jeff, Yang, Ping

“…Abstract Purpose Lung cancer survivors report the lowest quality of life relative to other cancer survivors. Pain is one of the most devastating, persistent,…”
Get full text

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors by Hubbard, Joleen, Erlichman, Charles, Toft, David O., Qin, Rui, Stensgard, Bridget A., Felten, Sara, Ten Eyck, Cynthia, Batzel, Gretchen, Ivy, S. Percy, Haluska, Paul

“…Summary Purpose : To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin…”
Get full text

Abstract PD3-3: Impact of neoadjuvant chemotherapy on the clonal composition of breast cancer by Goetz, Matthew P, Barrett, Michael T, Kalari, Krishna R, Suman, Vera J, McLaughlin, Sarah A, Moreno-Aspitia, Alvaro, Moyer, Ann M, Northfelt, Donald W, Gray, Richard J, Sinnwell, Jason, Mahoney, Douglas, Barman, Poulami, Vedell, Peter, Tang, Xiaojia, Thompson, Kevin, Dockter, Travis, Jones, Katie, Felten, Sara J, Conners, Amy, Eckel-Passow, Jeanette, Sicotte, Hughes, Hart, Steven N, Yu, Jia, Visscher, Daniel W, Wieben, Eric D, Schultz, Cloann, Liu, Minetta C, Ingle, James N, Wang, Liewei, Weinshilboum, Richard W, Boughey, Judy C

“…Abstract Background Cancer genomic investigations have identified recurrent genomic aberrations critical for cancer initiation, progression, and metastases…”
Get full text

Validation of rano criteria: Contribution of T2/FLAIR assessment in patients with recurrent glioblastoma treated with bevacizumab by Huang, Raymond Yi-kun, Rahman, Rifaquat, Pope, Whitney B., Ellingson, Benjamin M., Anderson, S. Keith, Felten, Sara J, Ballman, Karla V., Wu, Wenting, Nayak, Lakshmi, Lee, Eudocia Quant, Abrey, Lauren E., Galanis, Evanthia, Reardon, David A., Cloughesy, Timothy Francis, Wen, Patrick Y.

“…Abstract only…”
Get full text

Validation of EORTC Prognostic Factors for Adults with Low-Grade Glioma: a Report Utilizing Intergroup 86-72-511 by Daniels, Thomas B., Brown, Paul D., Felten, Sara J., Wu, Wenting, Buckner, Jan C., Arusell, Robert M., Curran, Walter J., Abrams, Ross A., Schiff, David, Shaw, Edward G.

Get full text

Abstract C56: NCCTG phase I trial of everolimus (RAD001) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients by Sarkaria, Jann N., Galanis, Evanthia, Peller, Patrick, Brown, Paul, Wu, Wenting, Felten, Sara, Uhm, Joon, Giannini, Caterina, Jaeckle, Kurt, Buckner, Jan

“…Abstract Background: The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival. We…”
Get full text

Quality of Life: The Assessment, Analysis, and Interpretation of Patient-Reported Outcomes by FAYERS, P. M. and MACHIN, D by Sloan, Jeff A., Dueck, Amylou, Qin, Rui, Wu, Wenting, Atherton, Pamela J., Novotny, Paul, Liu, Heshan, Burger, Kelli N., Tan, Angelina D., Szydlo, Daniel, Johnson, Victor M., Felten, Sara J., Zhao, Xinghua, Diekmann, Brent

Get full text

Quality of Life: The Assessment, Analysis, and Interpretation of Patient-Reported Outcomes by Sloan, Jeff A., Dueck, Amylou, Qin, Rui, Wu, Wenting, Atherton, Pamela J., Novotny, Paul, Liu, Heshan, Burger, Kelli N., Tan, Angelina D., Szydlo, Daniel, Johnson, Victor M., Felten, Sara J., Zhao, Xinghua, Diekmann, Brent

Get full text